Wednesday, July 22, 2026

Drug, Consumer and PFAS Dockets Drive a Concentrated Filing Day

New mass-tort intake remained concentrated in established dockets, with Depo-Provera (3140) supplying 19 filings through Murphy Law Firm and Comeaux Law Firm and placing pharmaceutical claims at the front of the day’s volume. Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability (2738) followed with 16 complaints, led by The Miller Firm LLC and Wagstaff Law Firm, reinforcing the firm concentration behind the talc docket’s continued intake. Environmental claims gained ground in Aqueous Film-Forming Foams Property Damage Products Liability (2873), where 12 filings included six from Napoli Shkolnik, while Hair Relaxer Marketing, Sales Practices, and Products Liability (3060) added seven through Johnson Law Group and Beasley Allen. Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability (3014) completed the top tier with four filings, all from Dicello Levitt LLP, leaving the day’s leading volume clustered around a limited group of mature proceedings. See the full filing feed and firm-level breakdowns here.

Port-Placement Cohort Narrows Thrombosis Timing Analysis

On July 21, 2026, a peer-reviewed cohort study evaluated venous thromboembolism after totally implantable port placement in 131 adult oncology patients. The study detected early catheter-related thrombosis in 2.29% of patients and recorded nine venous-thromboembolism events, or 6.87%, during a median 534-day follow-up. Its cumulative late-event incidence was 3.26% at 90 days, 5.94% at 180 days, and 8.05% at one year, while exploratory analyses identified no predictors of late events. The findings do not establish a product defect or causation in any individual port-catheter claim, but they focus timing analysis on the first six months after implantation.

POTW Study Focuses PFAS Source-Tracking Analysis

On July 22, 2026, the POTW Influent PFAS Study marked a regulatory data-collection development focused on PFAS entering publicly owned treatment works. Influent sampling can map municipal wastewater pathways, assess contaminant loading, and distinguish potential upstream contributors, while recognizing that treatment-plant influent often combines industrial, commercial, landfill, residential, and other inputs. The study does not establish individual exposure, general causation, or liability. For PFAS counsel, its practical significance lies in the analytical record it may supply for source-attribution, sampling-design, and allocation disputes.